Answers are grounded in this paper and cite their sources.
Investigates chemosensitivity and DNA damage responses in lymphoma, suggesting mechanisms of therapeutic resistance.
Delivering DNA damage is an established concept totreat cancer, but the precise mechanisms that determinewhether or not this damage will kill tumor cells are poorlyunderstood. Many anticancer agents are known to produce DNA damage upon interaction with specific intracellular targets (e.g., topoisomerases, DNA itself, and thereplication machinery). This damage, in turn, can produce catastrophic cell death owing to gross metabolicdysfunction or initiate a programmed response (e.g.,apoptosis) leading to the regulated death of the tumorcell. Resistance to catastrophic death presumably requires mutations that prevent the drug-target interaction,whereas resistance to programmed cell death can also involve effector defects that maintain viability despite substantial cellular damage. The relative impact of variousresistance mechanisms to clinical drug resistance is controversial and few have been validated in naturally occurring tumors...
No takes yet. Share an insight, caveat, or question.
Schmitt et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: